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Abstract
Background: Axial spondyloarthritis (axSpA) is an inflammatory disease associated
with significant diagnostic delays and is commonly missed in assessments of
persistent back pain.
Objective: To explore musculoskeletal physiotherapists' awareness, knowledge and
confidence in screening for signs, symptoms and risk factors of suspected axSpA and
criteria for rheumatology referral.
Design: An online UK survey was undertaken combining back pain vignettes
(reflecting axSpA, non‐specific back pain and radicular syndrome) and questioning
on features of suspected axSpA. Recruitment utilised online professional forums and
social media. Data analysis included descriptive statistics and conceptual content
analysis for free text responses.
Results: 132 survey responses were analysed. Only 67% (88/132) of respondents
identified inflammatory pathologies as a possible cause of persistent back pain. Only
60% (79/132) recognised the axSpA vignette compared to non‐specific low back
pain (94%) and radicular syndrome (80%). Most suspecting axSpA would refer for
specialist assessment (77/79; 92%). Awareness of national referral guidance was
evident in only 50% of ‘clinical reasoning’ and 20% of ‘further subjective screening’
responses. There was misplaced confidence in recognising clinical features of axSpA
(≥7/10) compared to knowledge levels shown, including high importance given to
inflammatory markers and human leucocyte antigen B27 (median ¼ 8/10).
Conclusions: Musculoskeletal physiotherapists may not be giving adequate consid-
eration to axSpA in back pain assessments. Awareness of national referral guidance
was also limited. Professional education on screening and referral for suspected
axSpA is needed to make axSpA screening and referral criteria core knowledge in
musculoskeletal clinical practice, supporting earlier diagnosis and better outcomes.
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1 | INTRODUCTION
Spondyloarthritis is an umbrella term for a group of systemic inflam-
matory disorders which includes axial spondyloarthritis (axSpA).
axSpA causes enthesitis involving inflammation of spinal ligamentous
and tendinous attachments to bone, which in its advanced stages can
lead to joint erosion and fusion of the vertebral and sacroiliac joints
(Danve & Deodhar, 2015; Kiltz, Baraliakos, Regel, Bühring, &
Brau, 2017; Sieper & Poddubnyy, 2017). A characteristic feature of
axSpA is persistent, and insidious back pain with inflammatory
features of prolonged morning stiffness and pain which improves with
movement but not with rest, termed ‘inflammatory back pain’ (Kiltz
et al., 2017). Other features of axSpA may include peripheral mani-
festations involving dactylitis, enthesitis (typically at the insertion of
the achilles tendon or plantar fascia) and inflammatory arthritis (Sieper
& Poddubnyy, 2017). There is also an association with extra‐articular
inflammatory conditions of uveitis, psoriasis and inflammatory bowel
disease (Danve & Deodhar, 2015; Sieper & Poddubnyy, 2017).
Axial Spondyloarthritis may underlie up to 5% of persistent back
pain presentations (McKenna, 2010) and is often mistaken as chronic
non‐specific back pain (Jois, Macgregor, & Gaffney, 2008; Tangrun-
gruengkit, Srinonprasert, & Chiowchanwisawakit, 2016). In the
United Kingdom, the median time to diagnosis has been reported as
8.5 years and has been much longer for some people (Derakhshan
et al., 2018). This delay in diagnosis prevents early intervention that
may reduce the disease progression (Seo et al., 2015; Sieper &
Poddubnyy, 2017) and the detrimental impacts on mood (Zhao
et al., 2018), function (Danve & Deodhar, 2015), ability to work
(Martindale, Shukla, & Goodacre, 2015) and complications including
osteoporosis and cardiovascular disease (Strand & Singh, 2017).
Research undertaken in general practice (GP) (Jois, et al., 2008;
Tangrungruengkit, et al., 2016) and specialities involved in extra‐
articular features of spondyloarthritis (Sykes, Hamilton, Jones, &
Gaffney, 2018; Villani et al., 2015) have explored potential reasons
for diagnostic delay. A lack of awareness of and screening for axSpA
is an important factor.
One challenge is that back pain is common across populations
with a lifetime prevalence of 60%–85% (Savigny, Watson, &
Underwood, 2009) compared to the estimated prevalence of axSpA
of 0.3%–1.2% (Danve & Deodhar, 2015; Kiltz et al., 2017). axSpA can
also behave similarly to non‐specific back pain problems and
degenerative disc disease in pain characteristics; insidious onset,
disturbed sleep and response to non‐steroid anti‐inflammatory
medications (Arnbak, Jurik, Jensen, & Manniche, 2018; Danve &
Deodhar, 2015; Jois et al., 2018; Sieper, Rudwaleit, et al., 2009;
Strand & Singh, 2017). Poor public awareness of axSpA is also a
factor (Harrison et al., 2014).
A cluster of features typical of ‘inflammatory back pain’ have been
identified in 89% of axSpA cases, which have formed the basis for
suspecting axSpA and the development of referral strategies
(Rudwaleit, van der Heijde, et al., 2009; Sieper, Rudwaleit, et al., 2009).
However, people with features of inflammatory back pain alone may
not always receive a diagnosis of axSpA (Arnbak et al., 2018; Danve &
Deodhar, 2015; Poddubnyy et al., 2011; Rudwaleit, van der Heijde,
et al., 2009). Signal changes (modic changes) at the vertebral body bone
marrow and neighbouring end plates seen on imaging in degenerative
discdisease canpresentas inflammatorybackpain (Arnbaketal., 2018)
and sacroiliac changes, such as bone marrow oedema and sclerosis, can
also occur in populations without axSpA (Weber et al., 2018).
The National Institute for Health and Care Excellence (NICE,
2017) have published clinical guidelines for axSpA to improve
recognition and earlier referral. The guidelines were developed to
reflect a balance of sensitivity, specificity and positive likelihood that
would detect the substantial majority of undiagnosed spondyloar-
thritis without overburdening specialist services (National Institute
for Health and Care Excellence, 2017). Awareness of the guideline
recommendations and referral criteria are important to help reduce
diagnostic delays and missing possible axSpA in back pain assess-
ments (McCrum, 2019; NHS England, 2017; NICE, 2017).
Although awareness and knowledge of axSpA has been explored
amongst General Practitioners and other medical specialities, as a
key profession assessing people with back pain, there has not been
research undertaken to date into awareness of and confidence of
musculoskeletal physiotherapists in assessing and referring for
features of possible axSpA. The aims of this study were to assess
physiotherapists' clinical reasoning and management decisions on
presentations of persisting back pain, ability to differentiate inflam-
matory back pain and axSpA from other back pain presentations, and
evaluate awareness of NICE guidance (NICE, 2016; NICE, 2017) on




Ethical approval was granted from the University of Hertfordshire,
Health and Human Sciences Ethics Committee (HSK/PGT/UH/
03202).
2.2 | Research design
A cross‐sectional online survey of musculoskeletal physiotherapists
working in the UK was undertaken from February to May 2018.
2.2.1 | Recruitment and sample population
Recruitment was directed at physiotherapists with at least one
experience in the assessment of persistent back pain. An initial sur-
vey question was used to filter out respondents who had never
treated a person with persistent back pain.
The survey was promoted through professional networks,
musculoskeletal forums and social media (Twitter, LinkedIn,
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Facebook and Physio Forum). Invitation emails were sent to post‐
graduate MSc students enrolled at the University of Hertfordshire,
physiotherapy members of National Axial Spondyloarthritis Society
(NASS) and AStretch, an axSpA specialist interest group. Permissions
were sought to promote the survey and respondents were asked to
snowball the survey to enhance response rates. Participation was
self‐selected and anonymous. On log‐in, a participant information
sheet was provided, and informed consent was assumed through
completion of the survey.
2.2.2 | Survey design
A multi‐strategy survey design was used which had three sections. A
draft survey received feedback from a selection of experienced
musculoskeletal physiotherapists, consultant rheumatologists and
researchers experienced in survey design before piloting with
several clinical physiotherapists using Bristol Online Survey Tool.
Amendments based on feedback were incorporated at both stages. The
development of the vignettes and clinical questions was informed by a
literature review, clinical practice guidelines and strategies utilised in
previous survey research. These included using the same age to avoid
age‐related factors (Bedson, Jordan, & Croft, 2003) and basing
presentation on real client cases (Bishop, Holden, Ogollah, &
Foster, 2016). The vignettes were designed to avoid ambiguity
between presentations and be typical of the three diagnoses (axSpA,
non‐specific back pain and radicular syndrome).
Section One contained case presentation vignettes of persistent
back pain (>3 months), each followed by a set of text questions. The
first vignette was common across all surveys and open‐ended ques-
tioning on screening for serious pathology and other differential di-
agnoses. This vignette and questioning were designed to assess
whether respondents included an inflammatory cause in responses.
The second vignette was a case presentation of either non‐specific
back pain or radicular syndrome. The third vignette was one of two
axSpA case presentations. These vignettes were all followed by the
same set of open‐ended questions. Two axSpA presentations were
developed to encompass the variability which can occur in respect to
inflammatory back pain, extra‐articular and peripheral manifesta-
tions. One of four variations of the vignette section was randomly
allocated to respondents. These vignettes were all followed by the
same set of open‐ended questions (One of the final four surveys is
provided in Data S1).
The vignettes were constructed using the NICE (2017) guideline
recommendations and referral criteria on spondyloarthritis and all
vignettes featured back pain persisting for longer than three months
with onset before 45 years of age. These features alone should
prompt consideration of possible axSpA.
The NICE (2017) guideline specifies nine additional features of
signs, symptoms and risk factors for suspected axSpA, whereby the
presence of four or more of these additional features should prompt
referral for to rheumatology. If three features are present, the
guidance recommends testing human leucocyte antigen B27 (HLA‐
B27) status. The two axSpA vignettes contained at least four of these
nine additional features and included pertinent features drawn from
previously published referral criteria: Assessment of Spondyloar-
thritis International Society (ASAS; Rudwaleit et al., 2009a, 2009b;
Sieper, van der Heijde, et al., 2009), European Spondyloarthropathy
Study Group (ESSG; Dougados et al., 1991) and Berlin criteria for
inflammatory back pain (Rudwaleit, Feldtkeller, & Sieper, 2006)
(see Table 1: Additional criteria from previously published referral
criteria).
These vignettes were followed by open‐ended questions asking
respondents for their primary and secondary diagnoses, their ‘clin-
ical reasoning’ and direction of ‘further subjective screening’ needed
and the management strategy for each vignette presentation.
Section Two was a knowledge and confidence questionnaire with
six sub‐sections. Sub‐section one evaluated respondents' knowledge
of signs, symptoms and risk factors for axSpA (using a 1 to 10‐point
scale where 1 meant ‘not at all important’ and 10 meant ‘very
important’ or a choice of unable to answer). Sub‐section two explored
self‐reported confidence in the knowledge required to recognise
features of suspected axSpA (using a 1 to 10‐point scale where 1
meant ‘not at all confident’ and 10 meant ‘very confident’). Sub‐
section three explored knowledge of importance of features when
considering an underlying inflammatory disease from a list of
inflammatory and non‐specific back pain features. Section four to six
explored awareness (yes/no) of the recently published NICE
guidelines and Quality Standards on low back and radicular pain
(NICE, 2016) and on spondyloarthritis (NICE, 2017), post‐graduate
training in back pain and spondyloarthritis and thoughts around the
need for further education into recognising spondyloarthritis. Section
Three sought demographic information.
There was no time limit on how long respondents could take to
complete the survey. The participant information sheet advised that
it would take approximately twenty minutes with Section One
requiring much of that time. This time was determined by feedback
on time burden from the respondents in the pilot process.
2.3 | Data analysis
Data was exported to Microsoft Excel® (Microsoft Corp) from Bristol
Online Survey (Jisc) and analysed using conceptual content analysis
and descriptive statistics (Robson & McCartan, 2016; Rossi, Serralvo,
& Joao, 2014). The content of the free‐text responses was analysed
by the main researcher (Eliza Steen ) for a priori features (based on
NICE (2017) guidance referral criteria) and emergent features,
assigned into categories and subcategories where applicable and
then assigned numerical codes (see Table 1).
Descriptive statistics were used to analyse the frequency of the
numerical codes within and across responses. The number of codes
within responses were used to reflect levels of awareness of the
signs, symptoms, and risk factors of axSpA and were graded; full
awareness, good awareness, poor awareness, or no awareness (see
Table 1). Associations were also analysed between vignette response
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results, guideline familiarity, confidence, level of knowledge and
various demographic data.
3 | RESULTS
One hundred and fifty physiotherapists responded to the survey, with
132 usable data sets following data clearing. Data sets were excluded
if incomplete, not working in the United Kingdom, or not a qualified
physiotherapist. Respondents' demographics are presented in Table 2.
3.1 | Section One: vignettes
Vignette 1: Screening of persistent back pain presentations for
serious pathology and other differential diagnoses.
In responses on screening required prior to physiotherapeutic
intervention, the following causes were identified; ‘inflammatory back
pathology’ 66% (n¼ 88/132), ‘red flags’ (expressed in various formats)
64% (n ¼ 85), ‘cancer’ 59% (n ¼ 78), ‘cauda equina syndrome’ 43%
(n ¼ 57), ‘infection’ 38% (n ¼ 51), ‘fracture’ 28% (n ¼ 37) ‘neurological
causes’ 28% (n ¼ 37) and ‘visceral pathology’ 25% (n ¼ 33).
Vignette 2 (non‐specific back pain or radicular syndrome) and
Vignette 3 (axSpA): Recognition of primary diagnosis of persistent
back pain case presentations.
Only 60% (n ¼ 79/132) of respondents correctly identified the
axSpA vignettes at primary diagnosis, compared with 94% (n ¼ 46/
49) for non‐specific back pain and 80% (n ¼ 66/83) for radicular
syndrome (see Figure 1). Failure to recognise the case presentation
was highest for the axSpA vignette at 23% (n ¼ 31/132).
Ninety‐four percent (n ¼ 50/53) of respondents with an incor-
rect primary diagnosis for the axSpA vignette misattributed the
presentation to non‐specific back pain.
There was an association between more accurate answers in the
axSpA vignette responses and familiarity with NICE guidance on
spondyloarthritis, continuing professional development (CPD) on
spondyloarthritis, working for the National Health Service (NHS),
receiving GP referrals and higher professional grade. Non‐recognition
of the axSpA vignette was associated with caseloads of ≤30% back
pain patients and ≤3 years musculoskeletal experience (Table 3).
TAB L E 1 Vignette analysis: Coding strategy applied to free text ‘clinical reasoning’ and ‘further subjective screening’ responses
Category and sub‐category
Features of suspected axSpA (as per NICE guidance referral criteria)—a
priori codes Code
Awareness of NICE (2017) guidance on SpA: Baseline referral
criteria
Back pain persisting longer than 3 months 1
Onset before 45 years of age 2
Awareness of NICE (2017) guidance on SpA: Additional criteria
� Full awareness ¼ All features are identified in vignette (5/5
or 4/4)
� Good awareness ¼ Most features are identified in vignette
(3  4/5 or 3/4)
� Poor awareness ¼ Some features are identified in vignette
(1  2/5 or 1  2/4)
� No awareness ¼ No features identified in vignette
(0/4 or 0/5)
Back pain before the age of 35 years 3
Waking during secnd half of night 4
Improvement with movement 5
aCurrent or past arthritis 6
aCurrent of past enthesitis 6
Buttock pain 7
Improvement within 48 h with NSAIDs 8
Family history of spondyloarthritis or psoriasis 9
Current or past psoriasis 10
Category Emergent features of suspected axSpA
Additional criteria from previously published referral criteriab
(which should raise suspicion of inflammatory disease/axial
spondyloarthritis)
Not relieved/worse with rest 11
Early morning stiffness 12
Investigations (e.g., CRP, HLA‐B27) 13
Insidious onset 14
Other extra‐articular conditions—uveitis, inflammatory bowel disease 15
Other peripheral signs/symptoms (e.g., dactylitis, synovitis) 16
24‐h pattern (e.g., general night pain) 17
Abbreviations: axSpA, axial spondyloarthritis; CRP, c‐reactive protein; HLA‐B27, human leucocyte antigen B27; NICE, National Institute for Health and
Care Excellence (NICE, 2017); NSAIDs, non‐steroidal anti‐inflammatory drugs; SpA, spondyloarthritis.
aArthritis and Enthesitis both coded the same as the vignette content could have been interpreted as either.
bAssessment of Spondyloarthritis International Society (ASAS) criteria (Rudwaleit et al., 2009a, 2009b; Sieper, van der Heijde, et al., 2009), ESSG
(Dougados et al., 1991) and Berlin criteria for inflammatory back pain (Rudwaleit et al., 2006).
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AxSpA vignette: Evaluation of ‘clinical reasoning’ and direction of
‘further subjective screening’. Applying the content analysis codes in
Table 1.
Only 4% (n ¼ 4/101) of respondents correctly identifying the
axSpA vignette mentioned the NICE guidance ‘baseline referral
criteria’ of back pain >3 months and onset before 45 years in their
‘clinical reasoning’ responses. Varying levels of features from the
NICE (2017) guideline ‘Additional criteria’ were included in 96%
(n ¼ 97/101) of the ‘clinical reasoning’ and 86% (n ¼ 87/101) of
‘further subjective screening’ responses.
Other valid features categorised under ‘Additional criteria from
previously published referral criteria’ were mentioned in 79%
(n ¼ 80/101) and 85% (n ¼ 86/101) of ‘clinical reasoning’ and ‘further
subjective screening’ responses, respectively.
3.2 | Clinical reasoning
Only 50% (n ¼ 51/101) of respondents who correctly identified the
suspected axSpA vignette as a primary or secondary diagnosis
demonstrated ‘full awareness’ or ‘good awareness’ of the spondy-
loarthritis guideline recommendations, as described in Table 1, within
‘clinically reasoning’ responses. ‘Full awareness’ or ‘good awareness’
TAB L E 2 Respondent demographics
Demographics (n ¼ 132)
Median IQR





Prefer not to say 2 2%
Physiotherapy grade:
Basic grade 9 7%
Senior grade 38 29%
Specialist 30 23%
Highly specialist 38 29%
Expert 5 4%
Not applicable 12 9%




<1 year 10 8%
1–3 years 14 11%
>3–5 years 10 8%
>5–10 years 39 30%
>10 years 59 45%










Primary care 49 44%
Secondary care 37 33%
Mixed 25 23%
Private 39 30%




T A B L E 2 (Continued)
Demographics (n ¼ 132)
Median IQR
Years qualified 13 8–21
number %
Referral sources of LBP patientsa:
Consultant 85 64%
GP 109 83%









BACK PAIN 115 87%
SpA (n ¼ 121) 71 54%
Abbreviations: GP, general practitioner; IQR, inter‐quartile range; LBP,
low back pain; NHS, National Health Service; pts, patients; SpA,
spondyloarthritis.
aRespondents could indicate multiple responses.
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was demonstrated by 61% (n ¼ 37/61) of respondents familiar with
the NICE (2017) guidelines, compared to 33% (n ¼ 13/40) of those
not familiar (Figure 2).
3.3 | Further subjective screening
Only 20% (n ¼ 20/101) of respondents who correctly identified the
suspected axSpA vignette demonstrated ‘full awareness’ or ‘good
awareness’ of the spondyloarthritis guideline recommendations
within ‘further subjective screening’ responses. ‘Full awareness’ or
‘good awareness’ was demonstrated by 23% (n ¼ 14/61) of re-
spondents familiar with the NICE guidelines, compared to 15%
(n ¼ 6/40) of those not familiar (see Figure 3).
3.3.1 | Management strategy decision for axSpA
vignette
An appropriate management decision of referral for specialist opinion
was chosen by 92% (n ¼ 73/79) of respondents who correctly
identified the axSpA vignette at their primary diagnosis, with 61%
specifying referral to rheumatology. Only 23% (n ¼ 5/22) of re-
spondents who considered axSpA as a secondary diagnosis chose to
refer for specialist opinion, with 77% (n ¼ 17/22) choosing physio-
therapy management.
3.4 | Section 2: knowledge and confidence
questionnaire
3.4.1 | Importance of signs, symptoms and risk
factors for axSpA
Equally high importance (using a 1–10‐point scale where 1 meant
‘not at all important’ and 10 meant ‘very important’) was given to
elevated inflammatory markers, positive HLA‐B27 antigen, current or
history of psoriasis, inflammatory bowel disease, enthesitis, dactylitis
and synovitis (median (inter‐quartile range) ¼ 8, range 7–10) and
current or history of uveitis/iritis (median ¼ 8, range 8–10). Least
importance and more variability were observed for male gender as a
risk factor for axSpA (median ¼ 5, range 3–7).
3.4.2 | Confidence in recognising features of
suspected axSpA
Correctly identifying the axSpA vignette was associated with higher
self‐reported confidence (median ¼ 8/10) (using a 1–10‐point scale
where 1 meant ‘not at all confident’ and 10 meant ‘very confident’) in
knowledge of clinical features of inflammatory back pain, the extra‐
articular and peripheral features associated with spondyloarthritis
(see Figure 4). However, self‐reported confidence was still relatively
high in many respondents (59%) who inaccurately diagnosed the
axSpA vignette with a median of 7 for knowledge of inflammatory
back pain, and a median of 6 for the extra‐articular and peripheral
feature, although the overall range in self‐reported confidence was
much wider (see Figure 4).
3.4.3 | Knowledge of features of inflammatory back
pain
Only 27% of respondents recognised all features of inflammatory
back pain (9/9) based on a combination of ASAS (Rudwaleit
et al., 2009a, 2009b; Sieper, van der Heijde, et al., 2009), NICE (2017)
and Berlin criteria (Rudwaleit et al., 2006) (see Table 4 for all nine
features included in the question). The most recognised feature was
early morning stiffness >30 min, 87%; n ¼ 115/132. Only 64%
identified both NICE guidance baseline referral criteria (2/2) of
persistent back pain >3 months and onset before 45 years. Only 44%
identified all additional NICE (2017) referral criteria (4/4) and 70%
identified three referral criteria, whereby HLA‐B27 testing is then
recommended.
F I GUR E 1 Associations with identification of vignette diagnosis. Abbreviations: AxSpA, axial spondloarthritis; LBP, low back pain
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TAB L E 3 Association between individual respondent's demographics and their responses to the vignettes
Vignette diagnosis Suspected axial spondyloarthritis (n ¼ 132)
Diagnosis given by respondents
Primary diagnosis % (n) Secondary diagnosis % (n) Not recognised % (n)
All data (n ¼ 132) 60% (79) 17% (22) 23% (31)
NICE SpA Guideline Familiarity:
NICE—familiar 73% (52) 13% (9) 14% (10)
NICE—not familiar 44% (27) 21% (13) 34% (21)
Back pain training:
Yes 60% (73) 17% (21) 22% (27)
No 55% (6) 9% (1) 36% (4)
SpA training:
Yes 68% (50) 18% (13) 15% (11)
No 49% (23) 17% (8) 34% (16)
Experience (years):
<1 60% (6) 10% (1) 30% (3)
>1–3 21% (3) 36% (5) 43% (6)
>3–5 90% (9) 0% (0) 10% (1)
>5–10 59% (23) 18% (7) 23% (9)
>10 64% (38) 15% (9) 20% (12)
% back pain pts in overall caseload:
<30% 64% (7) 0% (0) 36% (4)
30% 53% (9) 12% (2) 35% (6)
40% 56% (15) 26% (7) 19% (5)
50% 65% (20) 10% (3) 26% (8)
60% 62% (8) 15% (2) 23% (3)
70% 56% (9) 25% (4) 19% (3)
>70% 65% (11) 24% (4) 12% (2)
NHS employed:
Yes 65% (72) 18% (20) 17% (19)
No 33% (7) 10% (2) 57% (12)
Physiotherapist grade:
Basic grade 33% (3) 33% (3) 33% (3)
Senior grade 53% (20) 21% (8) 26% (10)
Specialist 70% (21) 7% (2) 23% (7)
Highly specialist 74% (28) 18% (7) 8% (3)
Expert 80% (4) 20% (1) 0% (0)
Other 25% (3) 8% (1) 67% (8)
Referral source of back pain pts:
GP 62% (68) 17% (19) 20% (22)
No GP 48% (11) 13% (3) 39% (9)
Self‐referral 54% (39) 13% (31) 33% (29)
No self‐referral 67% (40) 22% (13) 12% (7)
Abbreviations: GP, general practitioner; NHS, National Health Service; SpA, spondyloarthritis; pts, patients.
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F I GUR E 2 Association between familiarity with National Institute for Health and Care Excellence spondyloarthritis guidelines and
awareness of features of suspected axial spondyloarthritis (axSpA). Abbreviation: axSpA, axial spondyloarthritis
F I GUR E 3 Association between familiarity with National Institute for Health and Care Excellence spondyloarthritis guidelines and
awareness of features of suspected axSpA. Abbreviations: axSpA, axial spondyloarthritis
F I GUR E 4 Association between
respondents' confidence in recognising
features of axSpA and recognition of axSpA
vignette diagnosis. n ¼ number of respondents
correctly identifying vignette (at primary or
secondary diagnosis) and number of
respondents who did not recognise axSpA
vignette diagnosis. Abbreviations: SpA,
spondyloarthritis
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Higher recognition of the features of inflammatory back pain was
associated with familiarity with the NICE (2017) guidance, working in
the NHS, prior education on spondyloarthritis and treating GP
referred patients.
4 | DISCUSSION
This study used an online survey using back pain presentation vi-
gnettes and a questionnaire to evaluate physiotherapists’ awareness,
knowledge and confidence in recognising axSpA. Analysis evaluated
respondents’ clinical reasoning and management decisions and
examined associations with demographic factors and clinician
characteristics.
The survey found limited awareness, knowledge and confidence
in the recognitions of features of inflammatory back pain, associated
extra‐articular conditions and peripheral features that are associated
with suspicion of spondyloarthritis. These findings have significant
implications concerning delayed diagnosis given that physiothera-
pists are commonly involved in the assessment and screening of
persistent back pain, and their role in appropriate and timely onward
referral for specialist assessment when indicated (Maher,
Underwood, & Buchbinder, 2017). Diagnostic delays in axSpA are
already significant (Derakhshan et al., 2018; Redeker et al., 2019) and
the survey findings suggest physiotherapist are an important target
for raising awareness of axSpA and professional education on
recognition and referral to improve this issue.
The finding in this study reflects research undertaken with
other key professions. General Practitioners and non‐rheumatolo-
gist physicians have demonstrated poor awareness of inflammatory
back pain and associated peripheral features and extra‐articular
inflammatory conditions (Jois et al., 2008; Tangrungruengkit
et al., 2016; van Onna, Gorter, Meerendonk & van Tubergen, 2014).
Only 5% of General Practitioners and 9.4% of non‐rheumatologists
identified all features indicative of inflammatory back pain
(Tangrungruengkit et al., 2016). Only 6% of General Practitioners
were found to consider all peripheral and extra‐articular features of
axSpA in their history taking (Jois et al., 2008). A recent UK survey
of osteopaths and chiropractors also highlighted a lack of awareness
and confidence in aspects of screening for possible axSpA (Yong
et al., 2019).
This survey also found that case presentations that were typical
of axSpA were commonly misattributed as persistent non‐specific
back pain. These findings reflect the difficulties that other healthcare
professionals have been found to encounter when differentiating the
symptoms of inflammatory back pain from non‐specific back pain
(Jois et al., 2008; Tangrungruengkit et al., 2016). Van Onna, Gorter,
van Meerendonk, and van Tubergen (2014) found that 40% of Gen-
eral Practitioners were unfamiliar with inflammatory back pain
symptoms and how to differentiate them from symptoms of non‐
specific back pain. Furthermore, Seo et al. (2015) found that 59% of
axSpA patients had previously been misdiagnosed, of which non‐
specific back pain was the diagnosis in 62% of cases.
Misattribution may be partly due to poor awareness of the
clinical features of axSpA, along with the common prevalence of non‐
specific back pain (90%–95% of back pain presentations) (Danve &
Deodhar, 2015; Sieper & Poddubnyy, 2017) and moves to reduce
over‐investigation and medicalisation of back pain (Foster
et al., 2018; NICE, 2016). There has been emphasis on the impor-
tance of appropriate screening within clinical history taking that has
included inflammatory back pain (Maher et al., 2017; NHS En-
gland, 2017; NICE, 2016). The lack of appropriate further subjective
screening found in this survey suggests that the questioning required
to identify possible axSpA is not core practice in back pain assess-
ments. Awareness of this element of assessments recommended in
NICE (2016) guidance on back and radicular pain, UK National Back
and Radicular Pain pathway (NHS England, 2017), and NICE (2017)
guidance on spondyloarthritis has not adequately filtered into
musculoskeletal practice and highlights the importance of an
awareness campaign on screening in back pain assessments and how
to question and recognise features of suspected axSpA.
The results of this survey suggest there is a lack of awareness of
when to refer to rheumatology. Many respondents who cited axSpA
as a secondary diagnosis in the suspected axSpA vignette inappro-
priately chose physiotherapy treatment rather than onward referral
in accordance with referral guidance (NICE, 2017). This finding is
significant given the diagnostic delays and importance of early
intervention (Danve & Deodhar, 2015; Strand & Singh, 2017). An
awareness raising campaign on recognition and referral of axSpA is
supported by the finding that better recognition and appropriate
referral were associated with respondents' familiarity with NICE
(2017) guidance on spondyloarthritis and previous professional ed-
ucation on spondyloarthritis. This association reflects research that
found improvements in history taking, raised awareness of spondy-
loarthritis and enhanced referral considerations in GP registrars
following a series of educational interventions (van Onna, Gorter,
Maiburg, Waagenaar, & van Tubergen, 2017) and supports the value
of professional education of physiotherapists on spondyloarthritis
screening and referral.
Better diagnostic accuracy was also associated with GP referred
caseloads and working within the NHS. These respondents also saw a
high proportion of back pain in their caseloads. The findings highlight
the importance of targeting educational campaigns and guideline
awareness beyond NHS settings and clinicians with low caseloads of
back pain presentations.
It was common for respondents to report confidence in recog-
nising clinical features of spondyloarthritis. However, the lack of
recognition of the axSpA vignettes and the poor awareness and
knowledge of the signs, symptoms and risk factors for axSpA
demonstrated in their clinical reasoning responses, or knowledge of
the referral criteria recommended by NICE (2017), suggests that this
confidence is misplaced. There was some awareness shown of pre-
viously published referral strategies developed by ASAS (Rudwaleit
et al., 2009a, 2009b; Sieper, van der Heijde, et al., 2009), the ESSG
(Dougados et al., 1991) and Berlin criteria (Rudwaleit et al., 2006).
However, the generally limited awareness of all these referral
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strategies indicates their lack of penetration into the physiotherapy
profession. This is unsurprising since there has been a paucity of
journal articles on axSpA published in core physiotherapy or
musculoskeletal health profession literature (McCrum, 2019). Survey
analysis found that prolonged morning stiffness as a symptom sus-
picious of inflammatory disease is strongly embedded in physio-
therapy screening practice.
Inflammatory back pain is considered the most recognisable
symptom of axSpA in rheumatology literature (Sieper et al., 2009a,
2009b) and respondents showed most confidence with inflammatory
back pain signs and symptoms as opposed to other associated features
of spondyloarthritis. This compares with a similar study in GP (Jois
et al., 2008). In the current survey, most respondents identified at least
three clinical features of spondyloarthritis yet showed limited
awareness of the same features within the axSpA vignettes, which,
resulted in misdiagnosis and lack of appropriate onward referral. This
discrepancy may relate to methodological limitations of the knowledge
evaluation strategy since the features were embedded in a list for
selection and may have resulted in false positive indications of
knowledge.
Confidence was disproportionally high for the recognition of
peripheral and extra‐articular features of axSpA since the associa-
tions with suspected axSpA were poorly identified in the vignettes.
These features also lacked mention in screening responses, and likely
reflect similar missed screening in clinical practice. Since the pres-
ence of these features raises index of suspicion of axSpA, screening in
back pain assessments is paramount (Danve & Deodhar, 2015;
NICE, 2017). As key musculoskeletal professions in back pain
assessment pathways, it is vital that physiotherapists should be
skilled in when to suspect axSpA.
Respondents also attributed high importance to pathology in-
vestigations in suspecting axSpA, including elevated CRP and ESR
and HLA B27 positivity. However, raised inflammatory markers, have
low sensitivity and specificity (Almodóvar et al., 2014) and present in
only 40%–50% of people with axSpA (Rudwaleit, Landewé,
et al., 2009). The high importance given to HLA‐B27 positivity may
indicate a lack of understanding in the role of risk factors in the
diagnosis of axSpA. Although a known risk factor for spondyloar-
thritis, HLA‐B27 positivity has a low specificity (Almodóvar
et al., 2014) and is present in the general population, with 8% posi-
tivity in Europeans (Sieper & Poddubnyy, 2017). NICE (2017) guid-
ance highlighted that inflammatory markers results and HLA‐B27
positivity or negativity do not rule in or rule out the possibility of
axSpA. The survey results suggest that an up‐to‐date understanding
of the role and interpretation of risk factors such as HLA‐B27 posi-
tivity and inflammatory marker results is an important aspect in
professional education on axSpA.
4.1 | Limitations
Several factors need consideration when interpreting the findings of
this study including response bias and the convenience and
self‐selected sample that is low compared to the numbers of prac-
ticing physiotherapists assessing back pain presentations in the
United Kingdom. A response rate of 132 usable results is not ex-
pected to be representative of all UK musculoskeletal physiothera-
pists. Respondents also tended to have more specialised
musculoskeletal experience which may be explained through the
targeted advertising of the survey. Respondents were predominantly
female, based in the NHS and England, and with many at a senior
level (band 6 as per Agenda for Change) which is representative of
the workforce (Chartered Society of Physiotherapists, 2017). Only
11% (14/132) of respondents had a specialist interest in Rheuma-
tology and so responses provided a sample that is reflecting the
breadth of expertise within clinical musculoskeletal practice.
Regardless of the limitations of the survey, results strongly indicate
that more emphasis must be put on raising awareness of axSpA and
its associated features and screening as part of routine clinical
practice, thus ensuring timely specialist referral (NICE, 2017).
5 | CONCLUSIONS
This survey gives insight into physiotherapists' awareness, knowledge
and confidence in recognising and referring for possible axSpA in the
assessment of persistent back pain presentations. There was limited
awareness shown of the signs, symptoms and risk factors for axSpA,
which may have a role in diagnostic delays. There was also a common
misattribution of pertinent inflammatory back pain features to a
diagnosis of non‐specific back pain. An ability to identify features of
possible axSpA was associated with familiarity with NICE guidance on
spondyloarthritis (NICE, 2017) and having undertaken professional
education on spondyloarthritis. The findings indicate a need for pro-
fessional education on screening and recognition of possible axSpA
and when to refer to rheumatology. The survey offers a valuable
evaluation tool for evaluating professional awareness and knowledge
of axSpA and as an indicator for education needs. Further research is
needed, both within physiotherapy and other professions assessing
people with persistent back pain, to evaluate whether better aware-
ness and knowledge impacts on diagnostic delay of axSpA.
ACKNOWLEDGEMENTS
The University of Hertfordshire for supporting ES undertaking this
research. The National Axial Spondyloarthritis Society (NASS) for
funding support and aiding survey dessemintion. All the expert re-
viewers who provided feedback during the survey construction and
all those who participated in the online survey.
CONFLICT OF INTEREST
The authors declare that they have no competing interests.
AUTHOR CONTRIBUTION
ES was responsible for the conception and study design, literature
review, data collection and analysis, and interpretation of the data
and gaining ethical approval and drafting, submitting, and revising the
STEEN ET AL. - 11
manuscript. ES undertook this research study as part of her MSc in
Advanced Physiotherapy at the University of Hertfordshire.CMc
contributed to study design, research focus and data interpretation
and substantially contributed to the manuscript revisions. MC pro-
vided methodological advice and supervision of the research,
including gaining ethical approval. She provided feedback and expert
advice on the content of the manuscript. All authors agreed on the
article revisions and approved submission of the article.
ETHICS STATEMENT
Ethical approval was granted from the University of Hertfordshire,
Health and Human Sciences Ethics Committee (HSK/PGT/UH/03202).
DATA AVAILABILITY STATEMENT
The datasets used and/or analysed during the current study are




Almodóvar, R., Ríos, V., Ocaña, S., Gobbo, M., Casas, M.‐L., Zarco‐Montejo,
P., & Juanola, X. (2014). Association of biomarkers of inflammation,
cartilage and bone turnover with gender, disease activity, radiolog-
ical damage and sacroiliitis by magnetic resonance imaging in pa-
tients with early spondyloarthritis. Clinical Rheumatology, 33(2),
237–241. https://doi.org/10.1007/s10067-013-2349-5
Arnbak, B., Jurik, A. G., Jensen T. S., & Manniche, C. (2018). Association
between inflammatory back pain characteristics and magnetic
resonance imaging findings in the spine and sacroiliac joints.
Arthritis Care & Research, 70(2), 244–251. https://doi.org/10.1002/
acr.23259
Bedson, J., Jordan., K., & Croft, P. (2003). How do GPs use x rays to
manage chronic knee pain in the elderly? A case study. Annals of the
Rheumatic Diseases, 62(5), 450–454. https://doi.org/10.1136/
ard.62.5.450
Bishop, A., Holden, M. A., Ogollah, R. O., & Foster, N. E. (2016). Current
management of pregnancy‐related low back pain: A national
cross‐sectional survey of UK physiotherapists. Physiotherapy,
102(1):78–85. https://doi.org/10.1016/j.physio.2015.02.003
Chartered Society of Physiotherapy. (2017). CSP membership report UK
– England, NI, Scotland & Wales. Retrieved from http://www.csp.
org.uk/documents/csp-membership-report-uk-%02013;-england-ni-
scotland-wales
Danve, A., & Deodhar, A. (2015). Screening and referral for axial spon-
dyloarthritis‐‐need of the hour. Clinical Rheumatology, 34(6), 987–
993. https://doi.org/10.1007/s10067-015-2958-2
Derakhshan, M. H., Pathak, H., Cook, D., Dickinson, S., Siebert, S., &
Gaffney, K. (2018). Services for spondyloarthritis: A survey of pa-
tients and rheumatologists. Rheumatology, 57(6), 987–996. https://
doi.org/10.1093/rheumatology/kex518
Dougados, M., Linden, S. V. D., Juhlin, R., Huitfeldt, B., Amor, B., Calin, A., …
Zeidler, H. (1991). The European Spondyloarthropathy Study Group
preliminary criteria for the classification of spondyloarthropathy.
Arthritis & Rheumatism, 34(10), 1218–1227. https://doi.org/10.1002/
art.1780341003
Foster, N. E., Anema, J. R., Cherkin, D., Chou, R., Cohen, S. P., Gross, D. P.,
… Maher, C. G. (2018). Prevention and treatment of low back pain:
Evidence, challenges, and promising directions. The Lancet,
391(10137), 2368–2383. https://doi.org/10.1016/S0140-6736(18)
30489-6
Harrison, A. A., Badenhorst, C., Kirby, S., White, D., Athens, J., & Stebbings,
S. (2014). Comparison of rates of referral and diagnosis of axial
spondyloarthritis before and after an ankylosing spondylitis public
awareness campaign. Clinical Rheumatology, 33(7), 963–968. https://
doi.org/10.1007/s10067-014-2551-0
Jois, R. N., Macgregor, A. J., & Gaffney, K. (2008). Recognition of inflam-
matory back pain and ankylosing spondylitis in primary care. Rheu-
matology, 47(9), 1364–1366. https://doi.org/10.1093/rheumatology/
ken224
Kiltz, U., Baraliakos, X., Regel, A., Bühring, B., & Brau, J. (2017). Causes of
pain in patients with axial spondyloarthritis. Clinical & Experimental
Rheumatology, 35 Suppl(5), S102–S107.Retrieved from https://www.
clinexprheumatol.org/article.asp.?a¼12197
Maher, C., Underwood, M., & Buchbinder, R. (2017). Non‐specific low back
pain. The Lancet, 389(10070), 736–747. https://doi.org/10.1016/
S0140-6736(16)30970-9
Martindale, J., Shukla, R., & Goodacre, J. (2015). The impact of ankylosing
spondylitis/axial spondyloarthritis on work productivity. Best Prac-
tice & Research Clinical Rheumatology, 29(3), 512–523. https://doi.
org/10.1016/j.berh.2015.04.002
McCrum, C. (2019). When to suspect spondyloarthritis: A core skill in
musculoskeletal clinical practice. Musculoskeletal Science and Practice,
44, 102079. https://doi.org/10.1016/j.msksp.2019.102079
McKenna, F. (2010). Spondyloarthritis. Retrieved from https://www.
arthritisresearchuk.org/health-professionals-and-students/reports/
hands-on/hands-on-spring-2010.aspx
National Institute for Health and Care Excellence. (2016). Low back pain
and sciatica in over 16s: Assessment and management (NG 59).
Retrieved from https://www.nice.org.uk/guidance/ng59
National Institute for Health and Care Excellence. (2017). Spondyloar-
thritis in over 16’s: Recognition, diagnosis and management (NG65).
Retrieved from https://www.nice.org.uk/guidance/ng65
NHS England. (2017). National back and radicular pain pathway.
Retrieved from https://ba17bc65-2f2f4a2f9427cd68a3685f52.
filesusr.com/ugd/dd7c8a_caf17c305a5f4321a6fca249dea75ebe.pdf
Poddubnyy, D., Rudwaleit, M., Haibel, H., Listing, J., Märker‐Hermann, E.,
Zeidler, H., … Sieper, J. (2011). Rates and predictors of radiographic
sacroiliitis progression over 2 years in patients with axial spondy-
loarthritis. Annals of the Rheumatic Diseases, 70(8), 1369–1374.
https://doi.org/10.1136/ard.2010.145995
Redeker, I., Callhoff, J., Hoffmann, F., Haibel, H., Sieper, J., Zink, A., &
Poddubnyy, D. (2019). Determinants of diagnostic delay in axial
spondyloarthritis: An analysis based on linked claims and patient‐
reported survey data. Rheumatology, 58(9), 1634–1638. https://doi.
org/10.1093/rheumatology/kez090
Robson, C., & McCartan, K. (2016). Real world research (4th ed.). Chi-
chester, UK: John Wiley & Sons Ltd.
Rossi, G. B., Serralvo, F. A., & Joao, B. N. (2014). Content analysis. Brazilian
Journal of Marketing, 13(4), 39‐48. https://doi.org/10.5585/remark.
v13i4.2701
Rudwaleit, M., Feldtkeller, E., & Sieper, J. (2006). Easy assessment of axial
spondyloarthritis (Early Ankylosing Spondylitis) at the bedside.
Annals of the Rheumatic Diseases, 65(9), 1251–1252. https://doi.org/
10.1136/ard.2005.051045
Rudwaleit, M., van der Heijde, D., Landewé, R., Listing, J., Akkoc,
N., Brandt, J., … Siper, J. (2009a). The development of assessment of
SpondyloArthritis international society classification criteria for
axial spondyloarthritis (part II): Validation and final selection. Annals
of the Rheumatic Diseases, 68(6), 777–783. https://doi.org/10.1136/
ard.2009.108233
Rudwaleit, M., Landewé, R., van der Heijde, D., Listing, J., Brandt, J.,
Braun, J., … Sieper, J. (2009b). The development of assessment of
SpondyloArthritis international society classification criteria for
axial spondyloarthritis (part I): Classification of paper patients by
expert opinion including uncertainty appraisal. Annals of the
12 - STEEN ET AL.
Rheumatic Diseases, 68(6), 770–776. https://doi.org/10.1136/
ard.2009.108217
Savigny, P., Watson, P., & Underwood, M. (2009). Early management of
persistent non‐specific low back pain: Summary of NICE guidance.
BMJ, 338, b1805. https://doi.org/10.1136/bmj.b1805
Seo, M. R., Baek, H. L., Yoon, H. H., Ryu, H. J., Choi, H.‐J., Baek, H. J., & Ko,
K.‐P. (2015). Delayed diagnosis is linked to worse outcomes and
unfavourable treatment responses in patients with axial spondy-
loarthritis. Clinical Rheumatology, 34(8), 1397–1405. https://doi.org/
10.1007/s10067-014-2768-y
Sieper, J., & Poddubnyy, D. (2017). Axial spondyloarthritis. The Lancet,
390(10089), 73–84. https://doi.org/10.1016/S0140-6736(16)
31591-4
Sieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos‐
Vargas, R., … van der Heijde, D. (2009a). The assessment of Spon-
dyloArthritis international society (ASAS) handbook: A guide to
assess spondyloarthritis. Annals of the Rheumatic Diseases, 68(2), ii1–
ii44. https://doi.org/10.1136/ard.2008.104018
Sieper, J., van der Heijde, D., Landewé, R., Brandt, J., Burgos‐Vagas, R.,
Collantes‐Estevez, E., … Rudwaleit, M. (2009b). New criteria for in-
flammatory back pain in patients with chronic back pain: A real
patient exercise by experts from the assessment of SpondyloAr-
thritis international society (ASAS). Annals of the Rheumatic Diseases,
68(6), 784–788. https://doi.org/10.1136/ard.2008.101501
Strand, V., & Singh, J. A. (2017). Evaluation and management of the patient
with suspected inflammatory spine disease. Mayo Clinic Proceedings,
92(4), 555–564. https://doi.org/10.1016/j.mayocp.2016.12.008
Sykes, M. P., Hamilton, L., Jones, C., & Gaffney, K. (2018). Prevalence of axial
spondyloarthritis in patients with acute anterior uveitis: A cross‐
sectional study utilising MRI. Rheumatic & Musculoskeletal Diseases
Open, 4(1), e000553. https://doi.org/10.1136/rmdopen-2017-
000553.
Tangrungruengkit, M., Srinonprasert, V., & Chiowchanwisawakit, P.
(2016). Survey of Thai physicians regarding recognition and man-
agement of inflammatory back pain and spondyloarthritis. Journal of
the Medical Association of Thailand, 99(1), 40–50.
Van Onna, M., Gorter, S., Maiburg, B., Waagenaar, G., & van Tubergen, A.
(2017). GPs’ patterns of clinical assessment when faced with a
patient suspected for spondyloarthritis: A prospective educational
intervention study. BJGP Open, 1(1), 1, bjgpopen17X100689. https://
doi.org/10.3399/bjgpopen17X100689
Van Onna, M., Gorter, S., van Meerendonk, A., & van Tubergen, A. (2014).
General practitioners’ perceptions of their ability to identify and
refer patients with suspected axial spondyloarthritis: A qualitative
study. Journal of Rheumatology, 41(5), 897–901. https://doi.org/
10.3899/jrheum.131293
Villani, A. P., Rouzaud, M., Sevrain, M., Barnetche, T., Paul, C., Richard,
M.‐A., … Jullien, D. (2015). Prevalence of undiagnosed psoriatic
arthritis among psoriasis patients: Systematic review and meta‐
analysis. Journal of the American Academy of Dermatology, 73(2), 242–
248. https://doi.org/10.1016/j.jaad.2015.05.001
Weber, U., Jurik, A. G., Zejden, A., Larsen, E., Jørgensen, S. H., Rufibach, K.,
… Schmidt‐Olsen, S. (2018). Frequency and anatomic distribution of
magnetic resonance imaging features in the sacroiliac joints of young
athletes: Exploring “background noise” toward a data‐driven defi-
nition of sacroiliitis in early spondyloarthritis. Arthritis & Rheuma-
tology, 70(5), 736–745. https://doi.org/10.1002/art.40429
Yong, C. Y., Hamilton, J., Benepal, J., Griffiths, K., Clark, Z. E., Rush, A., …
Gaffney, K. (2019). Awareness of axial spondyloarthritis among
chiropractors and osteopaths: Findings from a UK web‐based sur-
vey. Rheumatology Advances in Practice, 3(2), rkz034. https://doi.org/
10.1093/rap/rkz034
Zhao, S., Thong, D., Miller, N., Duffield, S. J., Hughes, D. M., Chadwick, L.,
Goodson, & N. J. (2018). The prevalence of depression in axial
spondyloarthritis and its association with disease activity: A sys-
tematic review and meta‐analysis. Arthritis Research and Therapy,
20(1), 140‐149. https://doi.org/10.1186/s13075-018-1644-6
How to cite this article: Steen E, McCrum C, Cairns M.
Physiotherapists' awareness, knowledge and confidence in
screening and referral of suspected axial spondyloarthritis:
A survey of UK clinical practice. Musculoskeletal Care.
2021;1–13. https://doi.org/10.1002/msc.1537
STEEN ET AL. - 13
